Amy S. Paller, MD, of Feinberg School of Medicine at Northwestern University, noted that safety is of paramount importance when choosing which systemic therapy to use to treat children with atopic dermatitis (AD).
Amy S. Paller, MD, chair of the department of dermatology at Northwestern University's Feinberg School of Medicine, noted that safety is of paramount importance when choosing which systemic therapy to use to treat children with atopic dermatitis (AD).
Specifically, Paller claimed that biologics are currently the safest to use in children, but she explained that, as more is learned about them, Janus kinase (JAK) inhibitors may take over that title in the years to come.
Conversely, Paller noted that the long-term side effects of systemic therapies are not yet known, which, she emphasized, providers must be aware of when using them to treat children with AD.
Transcript
What are the long-term risks of systemic therapy use in children with AD?
One of the factors that we need to be concerned about with systemic medications in children is that we're talking about longer term than what we may be talking about [for] an adult who's taking a medication. If we start at 2 or 3 years of age, 6 years of age, 10 years of age, we've got a few decades more, potentially, than what we might be doing in treating an adult.
So, we do pay attention to safety; that's of paramount importance in any systemic therapy we choose for children. Right now, we think that the biologics are safest, but we also may, in a few years, as we learn more about the JAK inhibitors, feel very comfortable with their use, including in children who have atopic dermatitis for years on end.
However, of course, it may take a long period of time before we know about the long-term side effects, even of the biologics, and we have to be aware of that in using them for our patients who are very young with atopic dermatitis.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More